Before you cheer if the FDA “approves” the COVID-19 “vaccine”, consider that the injections are killing tens of thousands and injuring tens of millions of people around the world.
The FDA has a long history of approving dangerous and deadly drugs and food additives that were later pulled from the market, some as long as 50 years after approval.
How is that possible that in some cases 50 years passed before the “genius experts” at the FDA and CDC “discovered” the dangers from their “safe and effective” approved drugs?
Follow the money
In 1979, the FDA was thisclose to banning food additives until Synerga and Monsanto bribed the right people so they could add poison to food products to “preserve” them. These food additives are responsible for the rampant increase in obesity, cancer, diabetes and many other ailments ever since. These “additives” were all approved by the FDA.
The same year, the FDA increased the number of vaccines given to children. In 1980 1 in 5,000 children developed autism. Today, 1 in 38 children develop autism. The medical mafia does its best to discredit this reality, calling it a coincidence that childhood autism and neurological disorders increased in lockstep with the increase of vaccines. Before 1979 there were six vaccines given to children. Today there are more than 60. SIDS is caused by the injections. Sudden infant death syndrome did not exist until the medical mafia began its assault on Our children with the new vaccine schedule. These are facts. Another fact is that all drugs that were removed from the market as dangerous and deadly were first approved by the FDA as “safe and effective”. Like the COVID-19 death shots.
|Below are 35 drugs that have been recalled from the US market since the 1970s, some that had been in use since the 1930s. A sample of advertisements for only some of the drugs are included because there is a scarcity of ads for withdrawn drugs online due to manufacturers removing ads for withdrawn drugs as part of the agreement to no longer market the drugs. According to the FDA, a “drug is removed from the market when its risks outweigh its benefits. A drug is usually taken off the market because of safety issues with the drug that cannot be corrected, such as when it is discovered that the drug can cause serious side effects that were not known at the time of approval.” The FDA also takes into account the number of people taking a drug being considered for removal so as to not harm those patients.|
|1. Accutane (Isotretinoin)on the market for 27 YEARS|
Manufacturer: Hoffman-La Roche1982 to June 2009Cause for recall:
increased risk of birth defects, miscarriages, and premature births when used by pregnant women; inflammatory bowel disease; suicidal tendencies Over 7,000 lawsuits were filed against the manufacturer over the side effects including a $10.5 million verdict and two $9 million verdicts.
|2. Baycol (Cerivastatin)on the market for 3 YEARS|
Use: Cholesterol reduction
Manufacturer: Bayer A.G.1998 to Aug. 2001Cause for recall:
rhabdomyolysis (breakdown of muscle fibers that results in myoglobin being released into the bloodstream) which led to kidney failure; 52 deaths (31 in the US) worldwide; 385 nonfatal cases with most requiring hospitalization; 12 of the deaths were related to taking this drug in combination with gemfibrozil (Lopid)
|3. Bextra (Valdecoxib)on the market for 3.3 YEARS|
Use: NSAID (pain relief)
Manufacturer: G.D. Searle & Co.Nov. 20, 2001 to Apr. 7, 2005Cause for recall:
serious cardiovascular adverse events (like death, MI, stroke); increased risk of serious skin reactions (like toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme); gastrointestinal bleeding
The FDA determined that Bextra showed no advantage over other NSAID pain relievers on the market.Bernadette Tansey, “Hard Sell: How Marketing Drives the Pharmaceutical Industry/The Side Effects of Drug Promotion/Aggressive Ads for Painkillers Left More Patients Exposed to Risk,” www.sfgate.com, Feb. 27, 2005
|4. Cylert (Pemoline)on the market for 30 YEARS|
Use: Central nervous system stimulant to treat ADHD/ADD
Manufacturer: Abbott Laboratories1975 to Oct. 2010Cause for recall:
liver toxicity The FDA added a box warning to Cylert in 1999, alerting doctors and patients to the potential of liver damage. Abbott Laboratories, “Cylert,” American Journal of Diseases of Children, www.bonkersinstitute.org, 1976
|5. Darvon & Darvocet (Propoxyphene)on the market for 55 YEARS|
Use: Opioid pain reliever
Manufacturer: Xanodyne1955 to
Nov. 19, 2010Cause for recall:
serious toxicity to the heart; between 1981 and 1999 there were over 2,110 deaths reported The UK banned Darvon and Darvocet in 2005. The FDA was petitioned in 1978 and again in 2006 to ban the drug by the group Public Citizen. Christian Sinclair, “Are You Glad Darvocet Got Pulled by the FDA? Are You Sure?,” www.pallimed.org, Nov. 30, 2010
|6. DBI (Phenformin)on the market for 19 YEARS|
Manufacturer: Ciba-Geigy1959 to Nov. 1978Cause for recall:
lactic acidosis (low pH in body tissues and blood and a buildup of lactate) in patients with diabetes
|7. DES (Diethylstibestrol)on the market for 31 YEARS|
Use: synthetic estrogen to prevent miscarriage, premature labor, and other pregnancy complications
Manufacturer: Grant Chemical Co.1940 to 1971Cause for recall:
clear cell adenocarcinoma (cancer of the cervix and vagina), birth defects, and other developmental abnormalities in children born to women who took the drug while pregnant; increased risk of breast cancer, higher risk of death from breast cancer; risk of cancer in children of mothers taking the drug including raised risk of breast cancer after age 40; increased risk of fertility and pregnancy complications, early menopause, testicular abnormalities; potential risks for third generation children (the grandchildren of women who took the drug) but they are unclear as studies are just beginning Studies in the 1950s showed the drug was not effective at preventing miscarriages, premature labor, or other pregnancy complications. Barbara Hammes and Cynthia Laitman, “Pharmaceutical Company Advertisement for DES by the Grant Chemical Company, Brooklyn, NY, Printed in the American Journal of Obstetrics & Gynecology in 1957,” Journal of Midwifery and Women’s Health, www.medscape.com, 2003
|8. Duract (Bromfenac)on the market for 1 YEAR|
Use: Pain killer
Manufacturer: Wyeth-Ayerst LaboratoriesJuly 1997 to
June 26, 1998Cause for recall:
4 deaths; 8 patients requiring liver transplants; 12 patients with severe liver damage
Duract was labeled for maximum use of 10 days but patients often received/took more than 10 days worth of pills; all cases of death and liver damage involved patients taking pills for longer than 10 days.
|9. Ergamisol (Levamisole)on the market for 11 YEARS|
Use: Worm infestation; colon and breast cancers; rheumatoid arthritis
Manufacturer: Janssen PharmaceuticaMay 8, 1989 to 2000Cause for recall:
neutropenia (a type of low white blood cell count), agranulocytosis (a type of low white blood cell count), and thrombotic vasculopathy (blood clots in blood vessels) which results in retiform purpura (a purple discoloration of the skin that can sometimes require reconstructive surgery)
Levamisole is still used to treat animals with worm infestations in the US. It is also being found in street cocaine as an adulterant to increase euphoric qualities.
|10. Hismanal (Astemizole)on the market for 11 YEARS|
Manufacturer: Janssen Pharmaceutica1988 to
Aug. 13, 1999Cause for recall:
slowed potassium channels in the heart that could cause torsade de pointes (TdP; a heart condition marked by a rotation of the heart’s electrical axis) or long QT syndrome (LQTS; prolonged QT intervals)
|11. Lotronex (Alosetron)on the market for 0.8 YEAR|
Use: Irritable bowel syndrome (IBS) in women
Manufacturer: Prometheus Laboratories, Inc.Feb. 9, 2000 to Nov. 28, 2000Cause for recall:
49 cases of ischemic colitis (inflammation and injury of the large intestine); 21 cases of severe constipation (10 requiring surgery); 5 deaths; mesenteric ischemia (inflammation and injury of the small intestine) Lotronex was reintroduced to the US market in 2002 with restricted indication. Irritable Bowel Syndrome Self Help and Support Group, “Lotronex,” www.ibsgroups.org (accessed Jan. 6, 2014)
|12. Meridia (Sibutramine)on the market for 13 YEARS|
Use: Appetite Suppressant
Manufacturer: Knoll PharmaceuticalsNov. 1997 to
Oct. 2010Cause for recall:
increased cardiovascular and stroke risk FDA reviewer Dr. David Graham listed Meridia with Crestor, Accutane, Bextra, and Serevent as drugs whose sales should be limited or stopped because of their danger to consumers in Sep. 30, 2004 testimony before a Senate committee, calling the drugs “another Vioxx.”
|13. Merital & Alival (Nomifensine)on the market for 3 YEARS|
Manufacturer: Hoechst AG (now Sanofi-Aventis)1982 to 1985Cause for recall:
haemolytic anemia; some deaths due to immunohemolytic anemia
|14. Micturin (Terodiline)on the market for 2 YEARS|
Use: Bladder incontinence
Manufacturer: Forest LabsAug. 1989 to
Sep. 13, 1991Cause for recall:
QT prolongation and potential for cardiotoxicity
|15. Mylotarg (Gemtuzumab Ozogamicin)on the market for 10|
Use: Acute myeloid leukemia (AML, a bone marrow cancer)
Manufacturer: WyethMay 2000 to
June 21, 2010Cause for recall:
increased risk of death and veno-occlusive disease (obstruction of veins)
|16. Omniflox (Temafloxacin)on the market for 0.3 YEAR|
Use: Antibiotic for pneumonia, bronchitis, and other respiratory tract infections; prostatitis and other genitourinary tract infections; skin ailments.
Manufacturer: Abbot LaboratoriesJan. 31, 1992 to June 5, 1992Cause for recall:
3 deaths; severe low blood sugar; hemolytic anemia and other blood cell abnormalities; kidney disfunction (half of the cases required renal dialysis); allergic reactions including some causing life-threatening respiratory distress
|17. Palladone (Hydromorphone hydrochloride, extended-release)on the market for 0.5|
Use: Narcotic painkiller
Manufacturer: Purdue PharmaJan. 2005 to
July 13, 2005Cause for recall:
high levels of palladone could slow or stop breathing, or cause coma or death; combining the drug with alcohol use could lead to rapid release of hydromorphone, in turn leading to potentially fatally high levels of drugs in the system
|18. Permax (Pergolide)on the market for 19 YEARS|
Use: Parkinson’s disease
Manufacturer: Valeant1988 to Mar. 29, 2007Cause for recall:
valve regurgitation (a condition that causes the valves to not close tightly, which allows blood to flow backward over the valve) in the mitral, tricuspid, and aortic heart valves, which can result in shortness of breath, fatigue, and heart palpitations Permax is still available in the U.S. for veterinary use, specifically for pituitary pars intermedia hyperplasia or equine Cushing’s Syndrome (ECS) in horses.
|19. Pondimin (Fenfluramine)on the market for 24 YEARS|
Use: Appetite suppressant
Manufacturer: Wyeth-Ayerst1973 to
Sep. 15, 1997Cause for recall:
30% of patients prescribed the drug had abnormal echocardiograms; 33 cases of rare valvular disease in women; 66 additional reports of heart valve disease Pondimin is better known as “Fen-Phen” when prescribed with Phentermine.
|20. Posicor (Mibefradil)on the market for 1 YEAR|
Use: Calcium channel blocker (used to treat hypertension)
Manufacturer: Roche LaboratoriesJune 1997 to
June 1998Cause for recall:
fatal interactions with at least 25 other drugs (ex: common antibiotics, antihistamines, and cancer drugs) including astemizole, cisapride, terfenadine, lovastatin, and simvastatin Posicor was found by the FDA to offer no significant benefit over other anti-hypertensive or antianginal drugs, which made the risks of drug interactions “unreasonable.” Patients immediately switching from Posicor to another calcium channel blocker were at increased risk of going into shock within 12 hours of the drug switch.
|21. Propulsid (Cisapride)on the market for 7 YEARS|
Use: Severe nighttime heartburn associated with gastroesophageal reflux disease (GERD)
Manufacturer: Janssen Pharmaceutica1993 to July 14, 2000Cause for recall:
more than 270 cases of serious cardiac arrythmias (including ventricular tachycardia, ventricular fibrillation, torsades de pointes, and QT prolongation) reported between July 1993 and May 1999, with 70 being deaths. Propulsid is also banned in India (2011) and available for limited use in Europe. It is still available for use in animals in the US and
|22. PTZ & Metrazol (Pentylenetetrazol)on the market for 48 YEARS|
Use: Convulsive therapy for schizophrenia and other psychiatric conditions
Manufacturer: not known1934 to 1982Cause for recall:
uncontrollable seizures; pulled muscles; fractured bones; spine fractures in as many as 42% of patients
|23. Quaalude [Marketed as: Optimal, Sopor, Parest, Somnafac, and Bi-Phetamine T] (Methaqualone)on the market for 23 YEARS|
Use: Sedative and hypnotic
Manufacturer: William H. Rorer Inc. & Lemmon Company1962 to 1985Cause for recall:
mania; seizures; vomiting; convulsions; death Methaqualone was originally tested in India as a malaria treatment (it was ineffective). The drug is now a schedule 1 drug in the United States (like heroin, marijuana, and LSD). Res Obscura, “From Quacks to Quaaludes: Three Centuries of Drug Advertising,” www.resobscura.blogspot.nl, June 11, 2012
|24. Raplon (Rapacuronium)on the market for 2 YEARS|
Use: Non-polarizing neuromuscular blocker (used in anesthesia
Manufacturer: Organon Inc.1999 to
Mar. 27, 2001Cause for recall:
bronchospasms and unexplained deaths
|25. Raptiva (Efalizumab)on the market for 6 YEARS|
Manufacturer: Genentech2003 to
Apr. 8, 2009
(completely withdrawn by
June 8, 2009)Cause for recall:
progressive multifocal leukoencephalopathy (PML; a rare and usually fatal disease that causes inflammation or progressive damage of the white matter in multiple locations of the brain)
|26. Raxar (Grepafloxacin)on the market for 2 YEARS|
Use: Antibiotic for bacterial infections
Manufacturer: Glaxo Wellcome1997 to
Nov. 1, 1999Cause for recall:
cardiac repolarization; QT interval prolongation; ventricular arrhythmia (torsade de pointes)
|27. Redux (Dexfenfluramine)on the market for 1 YEAR|
Use: Appetite suppressant
Manufacturer: Wyeth-Ayerst1996 to Sep. 15, 1997Cause for recall:
30% of patients prescribed the drug had abnormal echocardiograms; 33 cases of rare valvular disease in women; 66 additional reports of heart valve disease Redux is better known as “Fen-Phen” when prescribed with Phentermine.
|28. Rezulin (Troglitazone)on the market for 3.25 YEARS |
Use: Antidiabetic and anti-inflammatory
Manufacturer: Parke-Davis/Warner Lambert (now Pfizer)Jan. 29, 1997 to Mar. 21, 2000Cause for recall:
at least 90 liver failures; at least 63 deaths About 35.000 personal injury claims were filed against the manufacturer (Pfizer).
|29. Selacryn (Tienilic acid)on the market for 3 YEARS|
Use: blood pressure
Manufacturer: SmithKlineMay 2, 1979 to 1982Cause for recall:
hepatitis; 36 deaths; at least 500 cases of severe liver and kidney damage Anphar Labs (which developed the drug in France and sold rights to sell in US to SmithKline) sent a report to SmithKline in Apr. 1979 (translated in May 1979 to English from French) stating Selacryn damaged livers. On Dec. 13, 1984, SmithKline Beckman plead guilty to “14 counts of failing to file reports with the drug agency of adverse reactions to Selacryn and 20 counts of falsely labeling the drug with a statement that there was no known cause-and-effect relationship between Selacryn and liver damage”
|30. Seldane (Terfenadine)on the market for 13 YEARS |
Manufacturer: Hoechst Marion Roussel (now Sanofi-Aventis)1985 to
Feb. 1, 1998Cause for recall:
life-threatening heart problems when taken in combination with other drugs (specifically erthromycin (an antibiotic) and ketoconazole (an antifungal) Seldane was not considered an imminent threat. The FDA pulled Seldane from the market because Allegra and Allegra D were produced by the same company and were deemed safer by the FDA.
|31. Trasylol (Aprotinin)on the market for 15 (48) YEARS|
Use: antifibrinolytic to reduce blood loss during surgery
Manufacturer: Bayer1993 (but used since the 1960s) to Nov. 5, 2007 (marketing suspension request to phase it out of the market);
May 14, 2008 (manufacturer announced complete removal from market)Cause for recall:
increased chance of death, serious kidney damage, congestive heart failure, and strokes On Feb. 8, 2006, the FDA issued a public heath advisory to surgeons who perform heart bypasses, alerting them of possible fatal side effects.
|32. Vioxx (Rofecoxib)on the market for 5.3 YEARS |
Use: NSAID (pain relief)
Manufacturer: MerckMay 20, 1999 to Sep. 30, 2004Cause for recall:
increased risk of heart attack and stroke; linked to about 27,785 heart attacks or sudden cardiac deaths between May 20, 1999 and 2003 Ads for Vioxx features Olympic gold medalists Dorothy Hamill and Bruce Jenner. Vioxx was prescribed to more than 20 million people. Today’s Seniors Network, “This Is Patient Education?,” www.todaysseniorsnetwork.com (accessed Jan. 7, 2014)
|33. Xigris (Drotrecogin alfa (activated))on the market for 10|
Use: Severe sepsis and septic shock
Manufacturer: Eli Lilly & CompanyNov. 2001 to
Oct. 25, 2011Cause for recall:
no survival benefit
|34. Zelmid (Zimelidine)on the market for 0 YEARS|
Manufacturer: Astra AB (now AstraZeneca)1982 to 1982 (withdrawn by the FDA before being released in the US market)Cause for recall:
Guillain–Barré syndrome; higher risk of suicide
|35. Zelnorm (Tegaserod maleate)on the market for 4.6|
Use: irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55
Manufacturer: NovartisJuly 24, 2002 to Mar. 30, 2007Cause for recall:
higher chance of heart attack, stroke, and unstable angina (heart/chest pain) The FDA permitted restricted use of Zelnorm on an emergency basis (with prior case-by-case authorization from the FDA) on July 27, 2007. Adforum.com, “Zelnorm – ‘N/A’ – Deutsch NY,” www.adforum.com (accessed Feb. 7, 2014)
Adforum.com, “Zelnorm – ‘N/A’ – Deutsch NY,” www.adforum.com (accessed Feb. 7, 2014)
AP, “Drug Maker Pleads Guilty over Lethal Side Effects,” www.nytimes.com, Dec. 14, 1984
AstraZeneca, “AstraZeneca Decides to Withdraw Exanta TM,” www.astrazeneca.com, Feb. 14, 2006
Michelle R. Carter and Sorour Amirhaeri, “p-ANCA-Associated Vasculitis Caused by Levamisole-Adulterated Cocaine: A Case Report,” Case Reports in Emergency Medicine, www.hindawi.com, 2013
Marlene Cimons, “Seldane Pulled for a Safer Allergy Drug,” www.latimes.com, Dec. 30, 1997
Dan Collins, “Insider: FDA Won’t Protect Public,” www.cbsnews.com, Dec. 7, 2004
Richard DeGrandpre, The Cult of Pharmacology: How America Became the World’s Most Troubled Drug Culture, 2006
“Drugs: The Dangers of Analgesics,” www.time.com, Feb. 24, 1967
Drugwatch, “What Is Accutane? It’s Uses and Interactions,” www.drugwatch.com/accutane, Dec. 10, 2013
Fairfield State Hospital, “Metrazol Therapy,” www.fairfieldstatehospital.com, Jan. 15, 2013
FDA, “FDA Alerts Consumers of Undeclared Drug Ingredients in Over-the-Counter Diabetes Product,” www.fda.gov, July 23, 2013
FDA, “FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen),” www.fda.gov, Sep. 15, 1997
FDA, “FDA Announces Voluntary Withdrawal of Pergolide Products: Agency Working with Product Manufacturers,” www.fda.gov, Mar. 29, 2007
FDA, “FDA Approves First Treatment for Women with Constipation-Predominant Irritable Bowel Syndrome,” www.web.archive.org, July 24, 2002
FDA, “FDA Drug Safety Communication: Voluntary Market Withdrawal of Xigris [drotrecogin alfa (activated)] Due to Failure to Show a Survival Benefit,” www.fda.gov, Oct. 25, 2011
FDA, “FDA Issues Public Health Advisory for Trasylol,” www.fda.gov, Feb. 8, 2006
FDA, “FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market,” www.fda.gov, June 21, 2010
FDA, “FDA Requests Marketing Suspension of Trasylol,” www.fda.gov, Nov. 5, 2007
FDA, “How Does FDA Decide When a Drug Is not Safe enough to Stay on the Market,” www.fda.gov, Jan. 7, 2010
FDA, “Information for Healthcare Professionals: Pemoline Tablets and Chewable Tablets (marketed as Cylert),” www.fda.gov, Oct. 2005
FDA, “Information for Healthcare Professionals: Valdecoxib (marketed as Bextra),” www.fda.gov, Apr. 7, 2005
FDA, “Propulsid (cisapride) Dear Healthcare Professional Letter Jan 2000,” www.fda.gov, Jan 24, 2000
FDA, “Propoxyphene: Withdrawal – Risk of Cardiac Toxicity,” www.fda.gov, Nov. 19, 2010
FDA, “Public Health Advisory: Suspended Marketing of Palladone (hydromophone hydrocloride, extended-release capsules),” www.fda.gov, July 13, 2005
FDA, “Questions and Answers about Withdrawal of Duract,” www.fda.gov, Aug. 23, 2013
FDA, “Questions and Answers about Withdrawal of Fenfluramine (Pondimine) and Dexfenfluramine (Redux),” www.fda.gov, July, 7, 2005
FDA, “Raplon (Rapacuronium Bromide),” www.fda.gov, Mar. 29, 2001
FDA, “Recalling the Omniflox (Temafloxacin) Tablets,” June 5, 1992
FDA, “FDA Statement on the Voluntary Withdrawal of Raptiva from the U.S. Market,” www.fda.gov, Apr. 8, 2009
FDA, “Withdrawal of Product: RAXAR (grepafloxin HCL) 600 mg Tablets, 400 mg Tablets, and 200 mg Tablets,” www.fda.gov, Nov. 1, 1999
FDA, “Zelnorm (tegaserod maleate) Information,” www.fda.gov, May 11, 2012
Jef Feeley, “Pfizer Ends Rezulin Cases with $205 Million to Spare (Update1),” www.bloomberg.com, Mar. 31, 2009
Barbara Forney, “Pergolide for Veterinary Use,” www.wedgewoodpetrx.com (accessed Jan. 6, 2014)
Curt D. Furgerg and Bertram Pitt, “Withdrawal of Cerivastatin from the World Market,” www.ncbi.nlm.nih.gov, Sep. 26, 2001
Raymond Goldberg, Drugs across the Spectrum, 6th edition, 2010
Barbara Hammes and Cynthia Laitman, “Pharmaceutical Company Advertisement for DES by the Grant Chemical Company, Brooklyn, NY, Printed in the American Journal of Obstetrics & Gynecology in 1957,” Journal of Midwifery and Women’s Health, www.medscape.com, 2003
David Healy, Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression, 2004
Charles D. Helper and Richard Segal, Preventing Medication Errors and Improving Drug Therapy Outcomes: A Management Systems Approach, 2003
Irritable Bowel Syndrome Self Help and Support Group, “Lotronex,” www.ibsgroups.org (accessed Jan. 6, 2014)
Harvey Kirk, “Darvon and Darvocet Deaths Lead FDA Panel to Recommend Recall,” www.youhavealawyer.com, Feb. 2, 2009
Lilly, “Lilly Announces Withdrawal of Xigris R Following Recent Clinical Trial Results,” www.fda.gov, Oct. 25, 2011
National Cancer Institute, “Diethylstilbestrol (DES) and Cancer,” www.cancer.gov, Oct. 5, 2011
Steven Morris, “Abbott Gets FDA Approval for Omniflox Antibiotic,” www.chicagotribune.com, Feb. 1, 1992
MSNBC Staff, “Report: Vioxx Linked to Thousands of Deaths,” www.nbcnews.com, Oct. 6, 2004
Pink Sheet, “FDA Clears Treatment IND for Colon Cancer Drug Levamisole,” www.elsevierbi.com, May 15, 1989
Res Obscura, “From Quacks to Quaaludes: Three Centuries of Drug Advertising,” www.resobscura.blogspot.nl, June 11, 2012
Rita Rubin, “How Did Vioxx Debacle Happen?,” www.usatoday.com, Oct. 12, 2004
Renato M.E. Sabbatini, “The History of Shock Therapy in Psychiatry,” www.crerbromente.org.br (accessed Dec. 19, 2013)
Christian Sinclair, “Are You Glad Darvocet Got Pulled by the FDA? Are You Sure?,” www.pallimed.org, Nov. 30, 2010
Ruth SoRelle, “Withdrawal of Posicor from Market,” www.circ.ahajournals.org, 1998
Sheryl Gay Stolberg, “New Painkiller Is Withdrawn after 4 Deaths,” www.nytimes.com, June 23, 1998
Bernadette Tansey, “Hard Sell: How Marketing Drives the Pharmaceutical Industry/The Side Effects of Drug Promotion/Aggressive Ads for Painkillers Left More Patients Exposed to Risk,” www.sfgate.com, Feb. 27, 2005
Forest Tennant, “Hughes & Pseudoaddiction,” Practical Pain Management, www.pain-topics.org, July/Aug. 2007
Today’s Seniors Network, “This Is Patient Education?,” www.todaysseniorsnetwork.com (accessed Jan. 7, 2014)
David Willman, “Diabetes Drug Rezulin Pulled Off the Market,” www.pulitzer.org, Mar. 22, 2000
David Willman, “Drug Lotronex Pulled over Safety Fears,” www.pulitzer.org, Nov. 29, 2000
Wei Zhang, Mary W. Roederer, Wang-Qing Chen, Lan Fan, and Hong-Hao Zhou, “Pharmacogenetics of Drugs Withdrawn from the Market,” Pharmacogenomics, www.medscape.com, 2012
WELCOME TO TRUTH TALK NEWS @ HowardNema.com
Take advantage of all the books, articles, links and suppressed information YOU NEED TO KNOW that is available on this site.
START YOUR JOURNEY BELOW:
BOOKS YOU MUST READ TO UNDERSTAND THE NEW WORLD ORDER is an ever growing catalogue of hundreds of books, articles, documents and research material on all things New World Order. Many of these books are very rare. Some are hundreds of years old. Combined, they create a path of breadcrumbs that lead to greater understanding the unseen forces behind most of the evil in this world, who have charted humanity’s progress throughout the ages and continue to do so.
Subscribe to Truth Talk News on twitter
STAND UP FOR FREE SPEECH!
WATCH AND SHARE TRUTH TALK NEWS!
“Where truth the mainstream media ignores is the top story!”
Let us take a journey together down the rabbit hole.
Watch TRUTH TALK NEWS, a talk show discussing suppressed history, current events, politics, pop culture, the esoteric and exoteric, and all things New World Order.
5pm WEDNESDAYS in Western Connecticut on Spectrum Cable Channel 192 serving the towns of Barkhamsted, Bethlehem, Bridgewater, Brookfield, Colebrook, Danbury, Harwinton, Kent, Monroe, New Hartford, New Fairfield, New Milford, Newtown, Roxbury, Sherman, Southbury, Trumbull, Washington, West Hartland, Winchester and Woodbury. Rebroadcasts THURSDAYS 9pm.
All information reported on TRUTH TALK NEWS and HowardNema.com is sourced and verifiable and for the purposes of education and FAIR USE. Take advantage of the many books, articles, videos and FULL PDF’s available for FREE, safe downloads on this site. TRUTH TALK NEWS and HowardNema.com ARE FREE SITES. All books and information on the sites are FREE and NOT monetized in any way.
You are not cattle.
You are not a useless eater.
Do the research.
Find your own truth.
There is only one truth. . . .
Seek and you will find it.
Thank you for your continued support. God bless you all. HN
All content herein can be used by anyone in accordance with U.S. Copyright law.
TRUTH TALK NEWS and HowardNema.com are free and independent of any network, group or association.
FAIR USE NOTICE: Some content displayed on this video/site may contain copyrighted material the use of which has not been specifically authorized by the copyright owner. This material has been made available in our efforts to advance understanding political, human rights, economic, democracy, scientific, and social justice issues, etc. constituting a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, all the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes